Lower blood 25 (OH) D concentration is associated with increased risk of islet autoimmunity (IA) in some cohorts; it is not known if 25 (OH) D metabolites are important after the onset of IA. We investigated novel vitamin D metabolites in development of IA and progression from IA to T1D in the Diabetes Autoimmunity Study in the Young (DAISY) . IA was defined as two or more consecutive visits positive for ≥ 1 autoantibody (IAA, IA-2A, GAD, ZnT8) . In a nested case-control study, we examined plasma vitamin D metabolites at a pre-seroconversion visit in 114 IA cases and 116 controls. We then followed 144 IA-positive children, of whom 46 developed T1D during a mean follow-up of 8.4 years. Plasma was quantified for 25 (OH) D3, 3-epi-25 (OH) D3, 25 (OH) D2, 24,25 (OH) 2D3, and 1,25 (OH) 2D3, using targeted LC-MS/MS. Logistic regression was used to examine pre-seroconversion metabolites and IA, and Cox regression was used to examine metabolites at seroconversion and progression to T1D. Both models adjusted for age, ethnicity, T1D family history and HLA-DR3/4. Higher pre-seroconversion level of 24,25 (OH) 2D3, an inactive catabolite of 25 (OH) D3, was associated with increased odds of IA (OR: 1.35; 95%CI: 1.03,1.78 per SD of 24,25 (OH) 2D3; p=0.031) . The association between 3-epi-25 (OH) D3 at seroconversion and progression from IA to T1D was modified by age at seroconversion. Higher 3-epi-25 (OH) D3 level was more protective against progression to T1D among children who seroconverted at an older age (HR: 0.47; 95%CI: 0.26, 0.85 for children at the 75th percentile of age at seroconversion (ie years)) compared to children who seroconverted at a younger age (HR: 0.88; 95%CI: 0.63, 1.24 for children at the 25th percentile (ie 3 years)) . Neither IA nor progression to T1D was associated with 25 (OH) D3, 25 (OH) D2 or 1,25 (OH) 2D3.Increased 24,25 (OH) 2D3 may play a role in IA development. The age-related heterogeneity of the relationship between 3-epi-25 (OH) D3 and T1D progression requires further investigation.

Disclosure

S.Kim: None. K.Kechris: None. O.Fiehn: None. M.Rewers: Consultant; Janssen Research & Development, LLC, Medscape, Provention Bio, Inc., Research Support; Dexcom, Inc., JDRF, Roche Diagnostics USA. J.M.Norris: None. N.L.Zwick: None. P.M.Carry: None. B.C.Defelice: None. R.K.Johnson: None. F.Dong: None. T.Buckner: None. L.A.Vanderlinden: None. B.I.Frohnert: Advisory Panel; Provention Bio, Inc.

Funding

National Institutes of Health (R01-DK104351, R01-DK32493, RI142483)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.